A Phase 2 interventional study of Cabozantinib in Advanced Renal Cell Carcinoma, sponsored by Takeda. Completed at 19 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-09-20.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing cabozantinib in Carcinoma, Renal Cell — 11 open to participants now, 23 under way, 4 of them phase 3. cabozantinib · Carcinoma, Renal Cell.
Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, this one is the 25th largest by enrollment, is one of 5 that started in 2017, is one of 25 in phase 2, and was the 11th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →11 of the 42 studies testing cabozantinib in Carcinoma, Renal Cell are open now, in 6 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
dr. Tom van der Hulle · Sites in Netherlands
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 70+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 27 · Phase 3 6 · Phase 4 1
First in 2010; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 44 across the 42 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 42 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 2 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
13 of the studies testing cabozantinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05263050Fox Chase Cancer CenterTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors | 2026-12 |
| NCT04413123Bradley A. McGregor, MDCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | 2026-12-20 |
| NCT06835972Memorial Sloan Kettering Cancer CenterA Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | 2027-02 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT07187869M.D. Anderson Cancer CenterModulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | 2027-04-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 42 studies testing cabozantinib in Carcinoma, Renal Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of cabozantinib measured by Independent Radiology Committee (IRC)-assessed objective response rate (ORR) in Japanese participants with advanced renal cell carcinoma (RCC) that has progressed after prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy.
The drug being tested in this study is called cabozantinib. Cabozantinib is being tested to treat people who have advanced renal cell carcinoma. This study will look at the efficacy of cabozantinib.
The study will enroll approximately 35 patients. Participants will be enrolled in one treatment group in non-randomized and opened manner:
All participants will be asked to take tablets of cabozantinib at once daily in the fasted state throughout the study.
This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately at most 3 years. Participants will make multiple visits to the clinic in treatment period, and posttreatment period including a follow-up assessment after last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the most recently received VEGFR-targeting TKI the following criteria must apply:
Radiographic progression is defined as unequivocal progression of existing tumor lesions or developing new tumor lesions as assessed by the investigator on computerized tomography (CT) or magnetic resonance imaging (MRI) scans.
Exclusion Criteria:
Participants with ongoing complications from prior radiation therapy are not eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.
Drug: Cabozantinib
Cabozantinib tablets
Also known as: XL184
Objective Response Rate (ORR)
ORR was defined as the percentage of participants whose best overall response was complete response (CR) or partial response (PR) evaluated by the independent review committee (IRC) per response evaluation criteria in solid tumors version 1.1 (RECIST V1.1) which was confirmed by a subsequent evaluation conducted ≥28 days later. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameter (SoD) of target lesions, taking as a reference the Baseline SoD.
Time frame: From first dose of study drug up to first documentation of CR or PR (up to 2.5 years)
Clinical Benefit Rate (CBR)
CBR was defined as percentage of participants whose best overall response is CR, PR, or stable disease (SD) per RECIST V1.1. Response and progression were evaluated by IRC per RECIST V1.1. CR and PR required confirmation by a subsequent evaluation conducted ≥28 days later and an assessment of SD was made at least 8 weeks after the first day of study drug. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: From first dose of study drug up to first documentation of CR or PR or SD (up to 2.5 years)
Progression-Free Survival (PFS)
PFS was defined as the time from the first day of study drug administration to the earlier of progressive disease (PD) per RECIST V1.1 or death due to any cause. Per RECIST V1.1, PD was defined at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline. In addition to the relative increase of 20%, the SoD also demonstrated an absolute increase of at least 5 mm.
Time frame: From first dose of study drug up to disease progression or death (up to 2.5 years)
Overall Survival (OS)
OS is defined as the time from the first day of study drug administration to death due to any cause.
Time frame: From first dose of study drug up to death due to any cause (up to 2.5 years)
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Percentage of Participants With Grade 3 or Higher TEAEs
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment. Severity grade was defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. As per the NCI-CTCAE, Grade 1 scales as mild; Grade 2 scales as moderate; Grade 3 scales as severe or medically significant but not immediately life-threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.
Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Percentage of Participants With Serious TEAEs
A serious TEAE was any untoward medical occurrence or effect that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was medically important due to other reasons than the above-mentioned criteria. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Percentage of Participants With TEAEs Leading to Permanent Treatment Discontinuation
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Percentage of Participants With TEAEs Leading to Dose Modification (Dose Reduction or Interruption)
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Percentage of Participants With Clinically Significant Abnormal Laboratory Values
Clinical laboratory tests included tests of serum chemistry, hematology, urine chemistry, coagulation, and thyroid function prespecified in the protocol. Only those categories are reported which are considered clinically significant abnormal laboratory values post baseline, as assessed by the investigator.
Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Percentage of Participants With Clinically Significant Abnormal Vital Sign
Vital signs included diastolic blood pressure (DBP) and systolic blood pressure (SBP) in the sitting position, pulse rate respiratory rate temperature, and weight. Abnormal vital sign values considered by the investigator to be clinically significant are reported as categories.
Time frame: From first dose up to 30 days after the last dose of the study drug (up to 2.6 years)
Participants took part in the study at 16 investigative sites in Japan from 13 December 2017 to 25 August 2020.
| Milestone | Cabozantinib 60 mg |
|---|---|
| Started | 35 |
| Completed | 0 |
| Not completed | 35 |
| Withdrew: Death | 12 |
| Withdrew: Site terminated by sponsor | 22 |
| Withdrew: Withdrawal by subject | 1 |
ORR was defined as the percentage of participants whose best overall response was complete response (CR) or partial response (PR) evaluated by the independent review committee (IRC) per response evaluation criteria in solid tumors version 1.1 (RECIST V1.1) which was confirmed by a subsequent evaluation conducted ≥28 days later. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in short axis to \<10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameter (SoD) of target lesions, taking as a reference the Baseline SoD.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| Objective Response Rate (ORR) | 25.7 (14.122 to 40.582) |
CBR was defined as percentage of participants whose best overall response is CR, PR, or stable disease (SD) per RECIST V1.1. Response and progression were evaluated by IRC per RECIST V1.1. CR and PR required confirmation by a subsequent evaluation conducted ≥28 days later and an assessment of SD was made at least 8 weeks after the first day of study drug. Per RECIST V1.1, CR was defined as the disappearance of all lesions, and all pathological lymph nodes (whether target or nontarget) must have a reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in SoD of target lesions, taking as a reference the Baseline SoD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| Clinical Benefit Rate (CBR) | 85.7 (69.743 to 95.194) |
PFS was defined as the time from the first day of study drug administration to the earlier of progressive disease (PD) per RECIST V1.1 or death due to any cause. Per RECIST V1.1, PD was defined at least a 20% increase in the SoD of target lesions, taking as a reference the smallest (nadir) SoD since (and including) Baseline. In addition to the relative increase of 20%, the SoD also demonstrated an absolute increase of at least 5 mm.
| months | Cabozantinib 60 mg |
|---|---|
| Progression-Free Survival (PFS) | 11.1 (7.4 to 18.4) |
OS is defined as the time from the first day of study drug administration to death due to any cause.
| months | Cabozantinib 60 mg |
|---|---|
| Overall Survival (OS) | NA (23.4 to NA) |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 100.0 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment. Severity grade was defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. As per the NCI-CTCAE, Grade 1 scales as mild; Grade 2 scales as moderate; Grade 3 scales as severe or medically significant but not immediately life-threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| Percentage of Participants With Grade 3 or Higher TEAEs | 82.9 |
A serious TEAE was any untoward medical occurrence or effect that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was medically important due to other reasons than the above-mentioned criteria. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| Percentage of Participants With Serious TEAEs | 42.9 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| Percentage of Participants With TEAEs Leading to Permanent Treatment Discontinuation | 17.1 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs whose date of onset occurs on or after the start of study drug and within 30 days after the last dose of study treatment.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| Dose Reduction | 88.6 |
| Dose Interruption | 80.0 |
Clinical laboratory tests included tests of serum chemistry, hematology, urine chemistry, coagulation, and thyroid function prespecified in the protocol. Only those categories are reported which are considered clinically significant abnormal laboratory values post baseline, as assessed by the investigator.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| White Blood Cells (WBC) Decreased | 17.1 |
| Absolute Neutrophil Count (ANC) Decreased | 5.7 |
| Lymphocytes Increased | 2.9 |
| Lymphocytes Decreased | 34.3 |
| Platelets Decreased | 20.0 |
| Hemoglobin Increased | 2.9 |
| Hemoglobin Decreased | 85.7 |
| Albumin Decreased | 88.6 |
| Alkaline Phosphatase (ALP) Increased | 65.7 |
| Amylase Increased | 57.1 |
| Alkaline Phosphatase (ALT) Increased | 74.3 |
| Aspartate Aminotransferase (AST) Increased | 80.0 |
| Corrected Calcium Increased | 5.7 |
| Corrected Calcium Decreased | 8.6 |
| Creatinine Increased | 97.1 |
| Gamma-glutamyl Transferase (GGT) Increased | 54.3 |
| Glucose Increased | 62.9 |
| Glucose Decreased | 5.7 |
| Lactate Dehydrogenase (LDH) Increased | 100 |
| Lipase Increased | 45.7 |
| Magnesium Increased | 14.3 |
| Magnesium Decreased | 77.1 |
| Phosphate Decreased | 54.3 |
| Potassium Increased | 14.3 |
| Potassium Decreased | 22.9 |
| Sodium Decreased | 48.6 |
| Total Bilirubin Increased | 17.1 |
| Urine Protein-to-creatinine Ratio (UPCR) Increased | 91.4 |
Vital signs included diastolic blood pressure (DBP) and systolic blood pressure (SBP) in the sitting position, pulse rate respiratory rate temperature, and weight. Abnormal vital sign values considered by the investigator to be clinically significant are reported as categories.
| percentage of participants | Cabozantinib 60 mg |
|---|---|
| BP Increased: SBP <120 millimeters of mercury (mmHg) and DBP <80 mmHg | 2.9 |
| BP Increased: SBP 120<= - <=139 mmHg or DBP 80<= - <=89 mmHg | 11.8 |
| BP Increased: SBP 140<= - <=159 mmHg or DBP 90<= - <=99 mmHg | 64.7 |
| BP Increased: SBP 160 mmHg<= and DBP <120 mmHg, or DBP 100<=- <=119 mmHg | 20.6 |
| Weight Decreased >=10% from Baseline | 37.1 |
Collected over Up to 2.6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib 60 mg | 12/35 (34.3%) | 15/35 (42.9%) | 35/35 (100%) |
| Event | Cabozantinib 60 mg |
|---|---|
| CholecystitisHepatobiliary disorders | 2/35 |
| PneumoniaInfections and infestations | 2/35 |
| Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/35 |
| IleusGastrointestinal disorders | 1/35 |
| Jaundice cholestaticHepatobiliary disorders | 1/35 |
| Lung infectionInfections and infestations | 1/35 |
| Amylase increasedInvestigations | 1/35 |
| Lipase increasedInvestigations | 1/35 |
| Pancreatic enzymes increasedInvestigations | 1/35 |
| Decreased appetiteMetabolism and nutrition disorders | 1/35 |
| Event | Cabozantinib 60 mg |
|---|---|
| DiarrhoeaGastrointestinal disorders | 24/35 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 23/35 |
| ProteinuriaRenal and urinary disorders | 17/35 |
| StomatitisGastrointestinal disorders | 15/35 |
| DysgeusiaNervous system disorders | 15/35 |
| HypertensionVascular disorders | 15/35 |
| Weight decreasedInvestigations | 14/35 |
| Hepatic function abnormalHepatobiliary disorders | 13/35 |
| MalaiseGeneral disorders | 11/35 |
| Decreased appetiteMetabolism and nutrition disorders | 11/35 |
Full Analysis Set (FAS) included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Cabozantinib 60 mg |
|---|---|
| Mean | 62.6 ± 9.81 |
| Sex: Female, Male(Participants) | Cabozantinib 60 mg |
|---|---|
| Female | 11 |
| Male | 24 |
| Race and Ethnicity Not Collected(Participants) | Cabozantinib 60 mg |
|---|
| Region of Enrollment(Participants) | Cabozantinib 60 mg |
|---|---|
| Japan | 35 |
| Memorial Sloan-Kettering Cancer Center (MSKCC) Risk Factors(Participants) | Cabozantinib 60 mg |
|---|---|
| Favorable Risk (0) | 11 |
| Intermediate Risk (1) | 19 |
| Poor Risk (2 or 3) | 5 |
| Heng Criteria(Participants) | Cabozantinib 60 mg |
|---|---|
| Favorable Risk (0) | 6 |
| Intermediate Risk (1-2) | 22 |
| Poor Risk (3-6) | 7 |
| Karnofsky Performance Status (PS)(Participants) | Cabozantinib 60 mg |
|---|---|
| 70 (Cares for self, unable to carry on normal activity or to do active work) | 1 |
| 80 (Normal activity with effort; some signs or symptoms of disease) | 5 |
| 90 (Able to carry on normal activity; minor signs or symptoms of disease) | 5 |
| 100 (Normal, no complaints, no evidence of disease) | 24 |
| Eastern Cooperative Oncology (ECOG) Group PS(Participants) | Cabozantinib 60 mg |
|---|---|
| Grade 0 | 26 |
| Grade 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2017 to primary completion in Aug 2020, 32 months.
Results were first posted in Sep 2021, 1 year after primary completion.
Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 32 months is close to that.
Counting every sponsor, half of 230 studies reached it within 58 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib